MINIMALLY INVASIVE MEDICAL DEVICE
EndoRNA qRT-PCR represents a breakthrough in the diagnosis of endometriosis. Its use allows early diagnosis and quicker initiation of specialised treatment. EndoRNA test result supports healthcare professionals in further diagnosis and treatment decisions.
EndoRNA qRT-PCR is a test intended for quantitative measurement of the relative level of the expression of the FUT4 gene – a marker for endometriosis. In the test, FUT4 mRNA data are expressed relative to the GAPDH reference gene. The analysis is performed on the endometrial tissue sample collected from a patient in the secretory phase of the menstrual cycle to confirm or exclude endometriosis.
DIAGNOSTIC PROCESS
Małoinwazyjny test laboratoryjny
PRODUCT ADVANTAGES
After the sample collection, the patient can resume her normal routines
Quick diagnostic process, even within 48 hours from the sample collection (depending on the laboratory workload), while it may take up to 8 years today.
Following the coronavirus pandemic, PCR technology became globally accessible
EndoRNA test is a registered medical device
Quick diagnosis enables healthcare professionals to provide treatment sooner
Other currently available markers, such as CA 125 or Bcl6, are not specific for endometriosis
DIAGNOSTIC EFFICienCY
A ratio of true positive results to the sum of true positive and false negative results
0
mln
women worldwide suffer from endometriosis
0
years
the average time needed to diagnose endometriosis using currently available methods
0
days
the average time needed to diagnose endometriosis using the innovative EndoRNA test
© Diagendo 2024